Allison O'Neill

Publications

1. Abscopal response in a patient with fibrolamellar hepatocellular carcinoma following radiotherapy. Lancet. 2025 Dec 21; 404(10471):2603-2604. View Abstract
2. Characteristics of patients with liver tumors deemed ineligible for enrollment on Children's Oncology Group trial AHEP1531: An opportunity to expand inclusion criteria and improve outcome. Pediatr Blood Cancer. 2025 Jan; 72(1):e31389. View Abstract
3. Outpatient Management of Fever and Neutropenia in Low-risk Children with Solid Tumors: A Quality Improvement Initiative. Pediatr Qual Saf. 2024 Sep-Oct; 9(5):e771. View Abstract
4. Upfront or delayed surgery in resectable hepatoblastoma: analysis from the children's hepatic tumors international collaboration database. EClinicalMedicine. 2024 Oct; 76:102811. View Abstract
5. Pediatric Adrenocortical Carcinoma: The Nuts and Bolts of Diagnosis and Treatment and Avenues for Future Discovery. Cancer Manag Res. 2024; 16:1141-1153. View Abstract
6. Clinical and immunophenotype correlating with response to immunotherapy in paediatric patients with primary liver carcinoma. A case series. EBioMedicine. 2024 Jun; 104:105147. View Abstract
7. Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature. J Clin Oncol. 2024 Jun 20; 42(18):2219-2232. View Abstract
8. Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center. Cancer Med. 2024 Apr; 13(8):e7154. View Abstract
9. Anti-CD99 Antibody Therapy Triggers Macrophage-Dependent Ewing Cell Death In Vitro and Myeloid Cell Recruitment In Vivo. Antibodies (Basel). 2024 Mar 18; 13(1). View Abstract
10. The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution. EClinicalMedicine. 2024 Mar; 69:102446. View Abstract
11. The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review. Oncologist. 2024 Feb 02; 29(2):106-116. View Abstract
12. Second Malignant Neoplasms Following Treatment for Hepatoblastoma: An International Report and Review of the Literature. J Pediatr Hematol Oncol. 2024 03 01; 46(2):80-87. View Abstract
13. Cancer Therapy-related Hepatic Injury in Children: Imaging Review from the Pediatric LI-RADS Working Group. Radiographics. 2023 09; 43(9):e230007. View Abstract
14. Evaluation of prevalence and outcomes of serial tyrosine kinase inhibitor use in pediatric patients with advanced solid tumors. Pediatr Blood Cancer. 2023 11; 70(11):e30652. View Abstract
15. Children's Oncology Group's 2023 blueprint for research: Liver tumors. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30576. View Abstract
16. Rare Tumors: Opportunities and challenges from the Children's Oncology Group perspective. EJC Paediatr Oncol. 2023 Dec; 2. View Abstract
17. Consensus classification of pediatric hepatocellular tumors: A report from the Children's Hepatic tumors International Collaboration (CHIC). Pediatr Blood Cancer. 2023 Jun 29; e30505. View Abstract
18. A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. Cancer Med. 2023 06; 12(12):13300-13308. View Abstract
19. Vincristine/irinotecan/temsirolimus upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 Study Committee. Pediatr Blood Cancer. 2023 07; 70(7):e30365. View Abstract
20. Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data. NPJ Precis Oncol. 2023 Mar 23; 7(1):29. View Abstract
21. Sodium thiosulfate as cisplatin otoprotectant in children: The challenge of when to use it. Pediatr Blood Cancer. 2023 05; 70(5):e30248. View Abstract
22. Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children's Hepatic Tumors International Collaboration (CHIC). Cancers (Basel). 2023 Jan 11; 15(2). View Abstract
23. Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: Report from Children's Oncology Group Trial, AHEP0731. J Pediatr Surg. 2022 Oct; 57(10):251-256. View Abstract
24. Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. J Hepatol. 2022 10; 77(4):1026-1037. View Abstract
25. A framework for fibrolamellar carcinoma research and clinical trials. Nat Rev Gastroenterol Hepatol. 2022 05; 19(5):328-342. View Abstract
26. Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee. J Clin Oncol. 2022 02 10; 40(5):459-467. View Abstract
27. Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study. Cancer. 2022 03 01; 128(5):1057-1065. View Abstract
28. Fibrolamellar carcinoma: An entity all its own. Curr Probl Cancer. 2021 08; 45(4):100770. View Abstract
29. Undifferentiated Embryonal Sarcoma of the Liver With Rhabdoid Morphology Mimicking Carcinoma: Expanding the Morphologic Spectrum or a Distinct Variant? Pediatr Dev Pathol. 2021 Nov-Dec; 24(6):564-569. View Abstract
30. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. Cancer Med. 2021 Apr; 10(7):2310-2318. View Abstract
31. A serous borderline ovarian tumour in a transgender male adolescent. Br J Cancer. 2021 02; 124(3):567-569. View Abstract
32. Timely pediatric cancer diagnoses: An unexpected casualty of the COVID-19 surge. Pediatr Blood Cancer. 2020 12; 67(12):e28729. View Abstract
33. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559. View Abstract
34. Making the most of small samples: Optimization of tissue allocation of pediatric solid tumors for clinical and research use. Pediatr Blood Cancer. 2020 09; 67(9):e28326. View Abstract
35. A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma. Oncologist. 2020 11; 25(11):925-e1603. View Abstract
36. The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database. Pediatr Blood Cancer. 2020 08; 67(8):e28350. View Abstract
37. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. Oncologist. 2020 12; 25(12):e1837-e1845. View Abstract
38. Correction: BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene. 2020 Mar; 39(12):2641. View Abstract
39. BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene. 2020 03; 39(11):2305-2327. View Abstract
40. a-Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. Cancer. 2019 10 15; 125(20):3649-3656. View Abstract
41. High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma. Clin Cancer Res. 2019 07 15; 25(14):4552-4566. View Abstract
42. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncol. 2019 05; 20(5):719-727. View Abstract
43. Long-term outcomes of liver transplantation for hepatoblastoma: A single-center 14-year experience. Pediatr Transplant. 2018 Jun 11; e13250. View Abstract
44. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. JAMA Oncol. 2017 12 01; 3(12):1634-1639. View Abstract
45. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. Pediatr Blood Cancer. 2018 Feb; 65(2). View Abstract
46. Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group. J Clin Oncol. 2017 Oct 20; 35(30):3465-3473. View Abstract
47. Hepatocellular Carcinoma in Fanconi-Bickel Syndrome. Pediatr Dev Pathol. 2018 Jan-Feb; 21(1):84-90. View Abstract
48. Unresectable hepatoblastoma: current perspectives. Hepat Med. 2017; 9:1-6. View Abstract
49. Cause and effect: the etiology of pediatric hepatocellular carcinoma and the role for liver transplantation. Pediatr Transplant. 2016 11; 20(7):878-879. View Abstract
50. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016 12; 130(3):495-503. View Abstract
51. Post-transplant lymphoproliferative disorder of the pediatric airway: Presentation and management. Int J Pediatr Otorhinolaryngol. 2016 Jul; 86:218-23. View Abstract
52. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody. Clin Cancer Res. 2014 Feb 01; 20(3):678-87. View Abstract
53. Loss-of-function and gain-of-function phenotypes of stomatocytosis mutant RhAG F65S. Am J Physiol Cell Physiol. 2011 Dec; 301(6):C1325-43. View Abstract
54. Ludwig's angina following frenuloplasty in an adolescent. Int J Pediatr Otorhinolaryngol. 2009 Sep; 73(9):1313-5. View Abstract
55. Ludwig's angina in the pediatric population. Clin Pediatr (Phila). 2009 Jul; 48(6):583-7. View Abstract
56. Immaturity of IL-18 gene expression and protein production in cord blood (CB) versus peripheral blood (PB) mononuclear cells and differential effects in natural killer (NK) cell development and function. Br J Haematol. 2005 Jul; 130(2):284-92. View Abstract
57. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005 May-Jun; 28(3):203-11. View Abstract
58. Are there universal parenting concepts among culturally diverse families in an inner-city pediatric clinic? J Pediatr Health Care. 2005 May-Jun; 19(3):142-50. View Abstract
59. Regulation of Ca(2+) signaling in rat bile duct epithelia by inositol 1,4,5-trisphosphate receptor isoforms. Hepatology. 2002 Aug; 36(2):284-96. View Abstract
60. Regulation of the type III InsP(3) receptor by InsP(3) and calcium. Biochem Biophys Res Commun. 2002 Jun 14; 294(3):719-25. View Abstract
61. The type II inositol 1,4,5-trisphosphate receptor can trigger Ca2+ waves in rat hepatocytes. Gastroenterology. 2002 Apr; 122(4):1088-100. View Abstract
62. A primitive ATP receptor from the little skate Raja erinacea. J Biol Chem. 2000 Sep 29; 275(39):30701-6. View Abstract
63. Primitive organization of cytosolic Ca(2+) signals in hepatocytes from the little skate Raja erinacea. J Exp Biol. 1999 Nov; 202(Pt 22):3049-56. View Abstract
Show All Publications Show Fewer Publications